MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common...
$27.89M
Proceeds from issuance of
common stock-At Market...
$9.126M
Proceeds from sale of
property and equipment
$0.009M
Proceeds from the
exercise of common stock...
$0.071M
Net cash provided by
financing activities
$36.57M
Net cash used in
investing activities
$0.009M
Canceled cashflow
$0.517M
Net increase
(decrease) in cash, cash...
$11.991M
Canceled cashflow
$24.588M
Payments on loan payable
$0.353M
Payment of employee
withholding taxes on vested...
$0.164M
Accounts payable and
accrued expenses
$3.51M
Equity-based compensation
$2.087M
Prepaid expenses and
other assets
-$1.173M
Amortization of right-of-use
assets
$0.192M
Realized loss on sale of
property and equipment
-$0.041M
Depreciation and
amortization
$0.036M
Net cash used in
operating activities
-$24.588M
Canceled cashflow
$7.039M
Grant income
$23.406M
Other segment items
-$0.906M
Net loss
-$23.487M
Grant receivables
$7.237M
Canceled cashflow
$24.312M
Deferred grant income and
other liabilities
-$0.699M
Operating lease
liabilities
-$0.204M
Clinical programs
$25.133M
General and
administrative expenses...
$9.617M
R&d personnel costs
$7.743M
Manufacturing
$2.543M
Equity-based compensation
$2.087M
Preclinical programs
$0.446M
Other research and
development expenses
$0.23M
Back
Back
Cash Flow
source: myfinsight.com
CGTX
CGTX